{"brief_title": "A Compassionate Treatment Protocol for the Use of Trimetrexate Glucuronate With Leucovorin Protection for Patients With Pneumocystis Carinii Pneumonia.", "brief_summary": "To provide trimetrexate glucuronate to immunosuppressed patients with Pneumocystis carinii pneumonia (PCP) for whom this investigational compound could provide significant medical benefit.", "detailed_description": "Patients receive intravenous infusions of trimetrexate glucuronate and leucovorin for 21 days. Leucovorin is continued for 3 additional days after discontinuation of trimetrexate glucuronate.", "condition": "HIV Infections", "intervention_type": "Drug", "intervention_name": "Leucovorin calcium", "criteria": "Inclusion Criteria Concurrent Medication: Allowed: - Antiretroviral therapy (at the discretion of the treating physician and/or medical monitor). Patients must have: - Presumptive or definitive diagnosis of Pneumocystis carinii pneumonia (PCP). - HIV positivity or be otherwise immunosuppressed. - Demonstrated intolerance and/or resistance to trimethoprim/sulfamethoxazole during the course of therapy for the current episode and not candidates for parenteral pentamidine, OR a documented history of such intolerance during a prior episode. - Consent of parent or guardian if less than 18 years of age. NOTE: - In general, patients who meet the eligibility criteria for other U.S. Bioscience-sponsored clinical trials for trimetrexate would not be eligible for this Compassionate Use protocol. Exclusion Criteria Patients with the following prior conditions are excluded: History of Type I hypersensitivity (i.e., urticaria, angioedema, or anaphylaxis), exfoliative dermatitis, or other life-threatening reactions to trimetrexate.", "gender": "All", "minimum_age": "N/A", "maximum_age": "N/A", "healthy_volunteers": "No", "id": "NCT00002102.xml"}